No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 40 of the 40 quarters in the window, leaving 0 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 1.9x · 10Y median 2.3x · 10th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T18:21:04.401Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Citius Pharmaceuticals, Inc. (CTXR) stock was $0.49 as of Oct 6, 2026, 2:19 PM EDT, down 6.65% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -61.9% · 3-year avg -68.5%/yr · 5-year avg -60.0%/yr
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products.
Biotechnology · Cranford, NJ
Next Earnings Date
Dec 17, 2026
72 days away
EPS Estimate
-0.41
Revenue Est.
$2.94M
Last Quarter Results
EPS
$-0.34
vs Estimate
$-0.36
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CTXR | $13.33M | $0.49 | -6.65% | -61.87% | -60.04% | -46.34% | N/A |
| 2OPTH | $13.30M | $4.13 | -3.84% | -49.89% | -21.80% | N/A | vs CTXR |
| 3PASG | $13.40M | $4.17 | +1.96% | -48.39% | -53.23% | N/A | vs CTXR |
| 4INAB | $13.14M | $1.37 | -3.52% | -40.44% | -62.88% | N/A | vs CTXR |
| 5SINT | $13.78M | $2.17 | -0.57% | N/A | N/A | N/A | vs CTXR |
| 6BFRG | $12.80M | $0.69 | +16.18% | -58.58% | N/A | N/A | vs CTXR |
forward FY estimate
N/A
$1.49M
vs Estimate
$5.46M
Consensus Rating
Based on 1 analyst
Average Price Target
$4.00
+724.1% upside
Low
$4.00
Current
$0.49
High
$4.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.41 | $-0.41 | $-0.41 | 1 |
| Quarter ending Dec 2026 | $-0.38 | $-0.38 | $-0.38 | 1 |
| Quarter ending Mar 2027 | $-0.38 | $-0.38 | $-0.38 | 1 |
| Quarter ending Jun 2027 | $-0.38 | $-0.38 | $-0.38 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.03 | $-2.03 | $-2.03 | 1 |
| FY 2027 | $-1.44 | $-1.44 | $-1.44 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $2.94M | $2.94M | $2.94M | 1 |
| Quarter ending Dec 2026 | $4.37M | $4.37M | $4.37M | 1 |
| Quarter ending Mar 2027 | $4.97M | $4.97M | $4.97M | 1 |
| Quarter ending Jun 2027 | $5.38M | $5.38M | $5.38M | 1 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $10.05M | $10.05M | $10.05M | 1 |
| FY 2027 | $20.52M | $20.52M | $20.52M | 1 |
